Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.
Innovation challenges continue to proliferate in the pharma industry, and Celgene is seeking crowdsourced solutions for multiple sclerosis patients.
With increasing numbers of novel biopharma platforms vying for a voice and money, it's more difficult for investors to assign them proper values.
The Cannes Lions Health pharma jury is now set, with the group set to meet in France for the festival and awards June 17 and 18.
AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.
Ionis has a long-standing reputation for being science driven, but in its 30-year history the company had never told its own story—until now.
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.
When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.
Cancer patients recount stories and offer advice in letters, looking back to when they were first diagnosed, in Merck’s new “With Love, Me” campaign.
AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.
